Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study

OBJECTIVES: The use of remdesivir (RDV) as the first drug approved for coronavirus disease 2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected patients (LEOSS), we aim to contribute timing-focused comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilgram, Lisa, Appel, Katharina S., Ruethrich, Maria M., Koll, Carolin E. M., Vehreschild, Maria J. G. T., de Miranda, Susana M. Nunes, Hower, Martin, Hellwig, Kerstin, Hanses, Frank, Wille, Kai, Haselberger, Martina, Spinner, Christoph D., Vom Dahl, Juergen, Hertenstein, Bernd, Westhoff, Timm, Vehreschild, J. Janne, Jensen, Björn-Erik Ole, Stecher, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913009/
https://www.ncbi.nlm.nih.gov/pubmed/36763285
http://dx.doi.org/10.1007/s15010-023-01994-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913009/
https://www.ncbi.nlm.nih.gov/pubmed/36763285
http://dx.doi.org/10.1007/s15010-023-01994-0

Ejemplares similares